Revolution Medicines announced it will present clinical data from its RAS(ON) inhibitor trials targeting pancreatic cancer at the ESMO Gastrointestinal Cancers Congress in July 2026. The presentations include Phase 1/2 trial results for zoldonrasib combined with chemotherapy or daraxonrasib, and Phase 3 trial posters for daraxonrasib in first-line and adjuvant settings for metastatic pancreatic adenocarcinoma. These data highlight the company's progress in developing targeted therapies for RAS-driven cancers, potentially advancing treatment options for this difficult-to-treat cancer. The event will be held in Munich, Germany, from July 1-4, 2026.
Mesoblast Limited has drawn $50 million from a new five-year loan facility provided by a shareholder, replacing higher-cost short-term debt. This move strengthens Mesoblast's balance sheet by lowering interest costs and removing short-term obligation...
HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 mont...
Western Union and Intermex announced that regulatory approvals for Western Union's acquisition of Intermex have been received from 51 U.S. states and international jurisdictions, with only one U.S. state, New York, pending approval. Both companies ar...
Modern Therapy Group has introduced a virtual intensive outpatient program (IOP) designed for adults dealing with depression, anxiety, trauma, and other mental health issues. This program offers structured, clinician-led treatment five days a week vi...
Meyer Wilson Werning, an investor protection law firm, is investigating UBS advisor Daniel Merithew Allen for allegedly recommending unapproved investments in 99 Acquisition Group LLC to clients. This practice, known as "selling away," violates FINRA...
